ActRIIA/B Program
Preservation/expansion of skeletal muscle mass as companion to GLP-1 RAs for obesity
Pre-clinicalActive
Key Facts
Indication
Preservation/expansion of skeletal muscle mass as companion to GLP-1 RAs for obesity
Phase
Pre-clinical
Status
Active
Company
About SixPeaks Bio
SixPeaks Bio is a private, pre-clinical-stage biotech focused on addressing a critical unmet need in the booming obesity therapeutics market: the loss of lean muscle mass associated with GLP-1-based weight loss drugs. The company's lead program targets ActRIIA/B (Activin Receptor Type IIA/B) to protect and potentially build muscle, positioning it as a potential combination therapy. Backed by a $110 million Series A financing and led by a team with deep experience in obesity drug development from major pharma, SixPeaks is leveraging its antibody and conjugate platform to build a pipeline of next-generation cardiometabolic therapies.
View full company profile